BIO Investor Forum 2005 to Webcast OrthoLogic Presentation

TEMPE, Ariz., Oct. 12  /PRNewswire-FirstCall/ -- OrthoLogic Corp. (NASDAQ:OLGC) announced today that management will provide an overview of the Company and an update on its lead compound for tissue and bone healing, Chrysalin(R), at the BIO Investor Forum 2005.  The presentation will be delivered at 1:40 p.m. PDT (4:40 p.m. EDT) on Thursday, October 20, 2005 from The Palace Hotel in San Francisco.

The presentation will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.orthologic.com/.  It will be archived for 30 days.

OrthoLogic is a biotechnology company focused on the development and commercialization of the novel synthetic peptide Chrysalin(R) (TP508) in three lead indications, all of which represent areas of significant unmet medical need -- fracture repair, diabetic foot ulcer healing and cartilage defect repair.  Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become the leading company focused on tissue and bone repair.  OrthoLogic is committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with equally under-served conditions.  The Company maintains exclusive worldwide rights for Chrysalin.  OrthoLogic's corporate headquarters are in Tempe, Arizona.  For more information, please visit the company's Web site: http://www.orthologic.com/. 

DATASOURCE: OrthoLogic Corp.



CONTACT:  Media, Lauren Tortorete of Biosector 2, [phone]; or

Investors, Melanie Friedman of Stern Investor Relations, [phone], both

for OrthoLogic Corp.



Web site:  http://www.orthologic.com/ 

Copyright